ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Increased platelet procoagulant activity driven by fibrin-GPVI interaction alters clot structure

J. Sandrin Gauer1, C. Duval2, R. Xu3, F. Macrae2, C. Tiede2, D. Tomlinson2, S. Watson4, R. Ariëns5

1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds., Leeds, England, United Kingdom, 2University of Leeds, Leeds, England, United Kingdom, 3Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds., Leeds, England, United Kingdom, 4University of Birmingham, Birmingham, UK, Birmingham, England, United Kingdom, 5Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, United Kingdom, Leeds, England, United Kingdom

Abstract Number: PB0383

Meeting: ISTH 2022 Congress

Theme: Platelets and Megakaryocytes » Platelet Receptors

Background: The GPVI-pathway has previously been reported to be involved in procoagulant platelet activity via GPVI-collagen binding. More recently, newly discovered fibrin-GPVI interactions have been reported to play a role in thrombosis. Nevertheless, the impact of GPVI-fibrin interaction on the development of procoagulant platelets, and how interfering with this interaction alters clot structure, remains to be established.

Aims: Our study aims were to investigate the role of GPVI-fibrin interaction on the development of procoagulant platelet and, subsequently, to characterize the effects of modulating GPVI-fibrin interaction on clot structure.

Methods: Procoagulant platelets were analysed in platelet-rich plasma (PRP) clots by SEM (wild-type and GPVI-deficient samples) and confocal microscopy. Procoagulant platelets were determined, and clot structure analysis assessing clot density, porosity, and retraction was performed in PRP or whole-blood clots from healthy volunteers in the presence of tyrosine kinase inhibitors (PRT-060318, ibrutinib and dasatinib), Affimer proteins inhibiting GPVI-fibrin(ogen) interaction, and eptifibatide control.

Results: In the presence of fibrin (and absence of collagen), GPVI-deficient clots, and clots where GPVI-fibrin(ogen) interaction or GPVI-signalling pathway were inhibited (by Affimer and tyrosine kinase inhibitors, respectively) showed fewer procoagulant platelets and decreased fibrin fibre density. Clot porosity was increased in the presence of all inhibitors, however, final clot weight following whole-blood clot retraction was altered only by ibrutinib. The effects of tyrosine kinase inhibitors on procoagulant platelet number were exacerbated by eptifibatide, which also significantly impaired whole-blood clot retraction.

Conclusion(s): Our results show that interaction of GPVI with fibrin plays a role in the development of procoagulant platelets and indicate that modulating this interaction has downstream effects on clot structure. Our findings suggest that targeting GPVI-fibrin interaction may alleviate structural characteristics commonly associated with a pro-thrombotic phenotype and, thereby, have important implications in development of novel anti-thrombotic interventions.

To cite this abstract in AMA style:

Sandrin Gauer J, Duval C, Xu R, Macrae F, Tiede C, Tomlinson D, Watson S, Ariëns R. Increased platelet procoagulant activity driven by fibrin-GPVI interaction alters clot structure [abstract]. https://abstracts.isth.org/abstract/increased-platelet-procoagulant-activity-driven-by-fibrin-gpvi-interaction-alters-clot-structure/. Accessed September 29, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/increased-platelet-procoagulant-activity-driven-by-fibrin-gpvi-interaction-alters-clot-structure/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley